Biosynex SA

ENXTPA:ALBIO Stock Report

Market Cap: €15.8m

Biosynex Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biosynex.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth15.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Oct 30
Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Aug 16
Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jun 29
Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12
Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20
Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05
Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01
Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Jun 23
Biosynex (EPA:ALBIO) Could Easily Take On More Debt

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Jul 11
If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Apr 06
Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Dec 19
We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosynex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ENXTPA:ALBIO - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024104-38-21-11N/A
3/31/202499-38-35-10N/A
12/31/202393-37-49-10N/A
9/30/202395-36N/AN/AN/A
6/30/202397-34-62-11N/A
3/31/2023147-9-47-3N/A
12/31/202219716-335N/A
9/30/202224840N/AN/AN/A
6/30/202230064N/AN/AN/A
3/31/202234184N/AN/AN/A
12/31/202138310491110N/A
9/30/2021359100N/AN/AN/A
6/30/202133596N/AN/AN/A
3/31/202124464N/AN/AN/A
12/31/2020154312332N/A
9/30/202010819N/AN/AN/A
6/30/2020617N/AN/AN/A
3/31/2020484N/AN/AN/A
12/31/2019351N/AN/AN/A
9/30/2019341N/AN/AN/A
6/30/2019331N/AN/AN/A
3/31/2019321N/AN/AN/A
12/31/2018311N/AN/AN/A
9/30/2018310N/AN/AN/A
6/30/2018310N/AN/AN/A
3/31/2018310N/AN/AN/A
12/31/2017310N/AN/AN/A
9/30/2017341N/AN/AN/A
6/30/2017381N/AN/AN/A
3/31/2017320N/AN/AN/A
12/31/2016270N/AN/AN/A
9/30/201620-1N/AN/AN/A
6/30/201612-1N/AN/AN/A
3/31/201611-1N/AN/AN/A
12/31/2015100N/AN/AN/A
9/30/201580N/AN/AN/A
6/30/201560N/AN/AN/A
3/31/20155-1N/AN/AN/A
12/31/20144-2N/AN/AN/A
9/30/20144-2N/AN/AN/A
6/30/20143-2N/AN/AN/A
3/31/20142-2N/AN/AN/A
12/31/20132-2N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALBIO's forecast earnings growth is above the savings rate (1.4%).

Earnings vs Market: Insufficient data to determine if ALBIO's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if ALBIO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALBIO's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if ALBIO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALBIO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 06:52
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biosynex SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laure PédurandEuroLand Corporate